Not sure if Sarepta sees Audentes as a threat in DMD given they’re preclinical and Sarepta already has plenty in the pipeline ?
Sarepta seem to have heavily pivoted the last few years building their gene therapy strong hold though so maybe just didn’t fit with them anymore ? Audentes buy out last night was big for Sarepta or all gene therapy companies really as the buy out spree continues.
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-36
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.010(7.69%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.5¢ | $308.5K | 2.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 358350 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 371822 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |